News >

Immunotherapy Combos Emerge as Standard Frontline Treatment in Advanced RCC

Ellie Leick
Published: Friday, Jan 10, 2020

David McDermott, MD

David McDermott, MD
The standard of care for treatment-naïve patients with advanced renal cell carcinoma (RCC) has shifted from a single-agent VEGF TKI to a checkpoint inhibitor plus either a VEGF TKI or a CTLA-4 inhibitor, explained David F. McDermott, MD.
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Publication Bottom Border
Border Publication